IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 527 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Article in PDF (47 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   References

 Article Access Statistics
    Viewed2637    
    Printed34    
    Emailed0    
    PDF Downloaded218    
    Comments [Add]    

Recommend this journal


Click on image for details.

  


 
LETTER TO EDITOR
Year : 2008  |  Volume : 74  |  Issue : 3  |  Page : 272-273

ErbB2: Nonimmune genetic key to leprosy

Bell Raj Eapen
Specialist Dermatologist, Kaya Skin Clinic, Dubai, United Arab Emirates

Correspondence Address:
Bell Raj Eapen
Kaya Skin Clinic, Dubai
United Arab Emirates
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.41386

Rights and Permissions



How to cite this article:
Eapen BR. ErbB2: Nonimmune genetic key to leprosy. Indian J Dermatol Venereol Leprol 2008;74:272-3

How to cite this URL:
Eapen BR. ErbB2: Nonimmune genetic key to leprosy. Indian J Dermatol Venereol Leprol [serial online] 2008 [cited 2019 Apr 21];74:272-3. Available from: http://www.ijdvl.com/text.asp?2008/74/3/272/41386


Sir,

I read with interest, the article titled "Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy" in the January 2008 issue of IJDVL. [1] It illustrates the growing importance of structural bioinformatics in clinical medicine and drug discovery. However, the use of the term 'ligand' in place of 'ligand-binding site' in the article could be misleading. A ligand is a molecule that is able to bind to and form a complex with a biomolecule to serve a biological purpose. Bioinformatics tools like Q-Site finder [2] predict putative binding sites within biomolecular structures after excluding bound ligands. ErbB2 has no known ligands [3] (unlike other ErbB receptors) and signalling is mediated through heterodimerization with ErbB3 or homodimerization with another ErbB2 (proposed mechanism of signalling in leprosy). [4] Docking studies and virtual high-throughput screening techniques are needed to identify unknown ligands (potential drug candidates) for ErbB2. [5]

Only extracellular Mycobacterium Leprae utilizes ErbB2 for downstream extracellular signal-regulated kinase (ERK) activation. [6] In contrast, lymphoid cell kinase (p56Lck) has been found to activate ERK 1/2 directly through a PKC e-dependent (Protein Kinase C e), MEK-independent (MEK = MAPK/Erk kinase; MAPK = Mitogen-activated protein kinase) pathway in intracellular Mycobacterium leprae . [7] Hence, ErbB2 inhibitors are unlikely to have a huge impact on leprosy therapeutics.

ErbB2 is a membrane protein with an extracellular region comprised of four domains, a single transmembrane helix and an intracellular region with a tyrosine kinase domain. [8] The structure (PDB: 2A91) used in the study, is a truncated one with three domains and 510 residues. [9] The structure of the entire extracellular region of ErbB2 bound to herceptin is available in PDB: 1N8Z. [10]

There is strong epidemiological evidence that genetic factors influence susceptibility to leprosy per se and to the leprosy type. Majority of the genes implicated in susceptibility to leprosy are immunity-related such as tumor necrosis factor-alpha (TNF-α) and interleukin (IL)-10. [11] A recent study of the spatial structure of the transmembrane domains of dimerized ErbB2 identified certain single-nucleotide polymorphisms (SNPs) which can excessively stabilize dimeric ErbB2 leading to spontaneous signalling. [12] Although the obvious relevance is its oncogenic potential, the possibility of a similar nonimmune mechanism that increases the susceptibility to leprosy, cannot be overlooked.

 
  References Top

1.Wiwanitkit V. Ligand-binding prediction for ErbB2, a key molecule in the pathogenesis of leprosy. Indian J Dermatol Venereol Leprol 2008;74:32-4.  Back to cited text no. 1    
2.Laurie AT, Jackson RM. Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005;21:1908-916.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]
3.Yarden Y. The EGFR family and its ligands in human cancer signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37:S3-8.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]
4.Tapinos N, Ohnishi M, Rambukkana A. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli. Nat Med 2006;12:961-6.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Taylor P, Blackburn E, Sheng YG, Harding S, Hsin KY, Kan D et al. Ligand discovery and virtual screening using the program LIDAEUS. Br J Pharmacol 2007;152:S55-67.  Back to cited text no. 5    
6.Noon LA, Lloyd AC. Treating leprosy: An Erb-al remedy? Trends Pharmacol Sci 2007;28:103-5.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Tapinos N, Rambukkana A. Insights into regulation of human Schwann cell proliferation by Erk1/2 via a MEK-independent and p56Lck-dependent pathway from leprosy bacilli. Proc Natl Acad Sci USA 2005;102:9188-93.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]
8.Bagossi P, Horvath G, Vereb G, Szollosi J, Tozser J. Molecular modeling of nearly full-length ErbB2 receptor. Biophys J 2005;88:1354-63.  Back to cited text no. 8    
9.Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell 2003;11:495-505.  Back to cited text no. 9  [PUBMED]  [FULLTEXT]
10.Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003;421:756-60.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]
11.Moraes MO, Cardoso CC, Vanderborght PR, Pacheco AG. Genetics of host response in leprosy. Lepr Rev 2006;77:189-202.  Back to cited text no. 11  [PUBMED]  
12.Bocharov EV, Mineev KS, Volynsky PE, Ermolyuk YS, Tkach EN, Sobol AG, et al. Spatial structure of dimeric transmembrane domain of the growth factor receptor ErbB2 presumably corresponding to the receptor active state. J Biol Chem 2008;283:6950-6.  Back to cited text no. 12  [PUBMED]  [FULLTEXT]




 
Top
Print this article  Email this article
Previous article Next article

    
Site Map  |  Contact Us  |  Feedback  |  Copyright and Disclaimer
Online since 15th March '04
Published by Wolters Kluwer - Medknow